GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This 'first ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted ...

Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...

A new study published in the journal of BMC Oral Health highlighted the role of salivary microbiota and polyamines in ...

A major investigation into the real-world effects of the JAK1 inhibitor abrocitinib, in a study called the "Abrocitinib CHinese rEgistry on AD" (AHEAD), made its international debut at the 83rd Annual ...

The Phase II trial examined the therapeutic cancer vaccine Tedopi in combination with chemotherapy drug combination FOLFIRI.

Brookline Capital Management upgraded shares of Perspective Therapeutics (NYSE:CATX – Free Report) to a strong-buy rating in a research note published on Monday,Zacks.com reports. Brookline Capital ...

"I wanted to spark a different conversation around menopause, one that empowers women and embraces it as a new beginning," ...

Bank of New York Mellon Corp boosted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 9.7% during the 4th quarter, according to its most recent disclosure with the ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...